Myocardial and circulating levels of microRNA-21 reflect left ventricular fibrosis in aortic stenosis patients

Villar, Ana V.; García, Raquel; Merino, David; Llano, Miguel; Cobo, Manuel; Montalvo, Cecilia; Martín‐Durán, Rafael; Hurlé, María A.; Nistal, J. Francisco

doi:10.1016/j.ijcard.2012.07.021

Cited by 136 publications

(101 citation statements)

References 52 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Molecular miRNA signaling pathways suggests miR-21 as a well-suited biomarker for early stages of fibrosis and remodeling on the one hand and as a promising target for disease treatment on the other [101][102][103][104][105][106][107]. Especially, in HFPEF, an early diagnosis of the disease is hard to make since functional assessment of the heart often reveals near normal parameters and clinical symptoms usually appear at later stages of disease progression.…”

Section: Mirnas As Circulating Biomarkers In the Differentiated Diagnmentioning

confidence: 99%

microRNAs in cardiovascular disease – clinical application

Schulte

Karakas

Zeller

2017

Clinical Chemistry and Laboratory Medicine (CCLM)

107

View full text Add to dashboard Cite

microRNAs (miRNAs) are well-known, powerful regulators of gene expression, and their potential to serve as circulating biomarkers is widely accepted. In cardiovascular disease (CVD), numerous studies have suggested miRNAs as strong circulating biomarkers with high diagnostic as well as prognostic power. In coronary artery disease (CAD) and heart failure (HF), miRNAs have been suggested as reliable biomarkers matching up to established protein-based such as cardiac troponins (cT) or natriuretic peptides. Also, in other CVD entities, miRNAs were identified as surprisingly specific biomarkers -with great potential for clinical applicability, especially in those entities that lack specific protein-based biomarkers such as atrial fibrillation (AF) and acute pulmonary embolism (APE). In this regard, miRNA signatures, comprising a set of miRNAs, yield high sensitivity and specificity. Attempts to utilize miRNAs as therapeutic agents have led to promising results. In this article, we review the clinical applicability of circulating miRNAs in CVD. We are giving an overview of miRNAs as biomarkers in numerous CVD entities to depict the variety of their potential clinical deployment. We illustrate the function of miRNAs by means of single miRNA examples in CVD.

show abstract

Section: Mirnas As Circulating Biomarkers In the Differentiated Diagnmentioning

confidence: 99%

microRNAs in cardiovascular disease – clinical application

Schulte

Karakas

Zeller

2017

Clinical Chemistry and Laboratory Medicine (CCLM)

107

View full text Add to dashboard Cite

show abstract

“…Relevance to human heart disease was provided subsequently on examination of plasma and biopsy samples in 75 patients with aortic stenosis. 54 Levels of miR-21 were increased in patients with aortic stenosis, but decreased after surgical correction of the valvular disease, and importantly, the level of miR-21 correlated with myocardial collagen level. Consistent with findings of prior groups, miR-21 expression was restricted to interstitial cells in the biopsy samples.…”

Section: Mir-21: Regulation Of Map Kinase Profibrotic Signalingmentioning

confidence: 89%

MicroRNAs in Heart Failure

Melman

Shah²,

Das³

2014

Circ: Heart Failure

101

View full text Add to dashboard Cite

“…120 Circulating miRNA may be involved in critical biological processes underlying cardiovascular disorders and are currently being investigated as biomarkers in cardiovascular disease. 121 Examples of potential miRNA biomarkers in AS include miR-133a, which was shown to predict the extent of regression of LV hypertrophy after SAVR 122 ; miR-21, which was shown to be associated with LV fibrosis 123 ; and miR-210, which was independently associated with mortality in patients with moderate-to-severe AS. 124 miRNA research is expected to expand considerably in the coming years, and new candidate biomarkers will likely be identified.…”

Section: Markers Of Alteration In Cardiac Metabolismmentioning

confidence: 99%

Biomarkers in Aortic Stenosis: A Systematic Review

et al. 2017

View full text Add to dashboard Cite

Aortic stenosis (AS) is one of the most common heart valve diseases among adults. When symptoms develop alongside severe AS, there is a poor prognosis unless aortic valve replacement (AVR) is performed; however, many patients do not report symptoms even when AS is severe. The optimal timing of AVR for these patients remains uncertain and controversial. AS is a heterogeneous disease with a complex pathophysiology involving structural and biological changes of the valve as well as adaptive and maladaptive compensatory changes in the myocardium and vasculature in response to chronic pressure overload. Several biomarkers reflecting these processes have been identified and have shown to have utility in predicting symptom onset and clinical events before and after AVR. Herein we systematically review biomarkers that have been studied in the setting of AS and summarize their potential use for risk stratification and ultimately to guide the optimal timing of AVR.

show abstract

Myocardial and circulating levels of microRNA-21 reflect left ventricular fibrosis in aortic stenosis patients

Abstract: Our results support the role of miR-21 as a regulator of the fibrotic process that occurs in response to pressure overload in AS patients and underscore the value of circulating miR-21 as a biomarker for myocardial fibrosis.

Cited by 136 publications

References 52 publications

microRNAs in cardiovascular disease – clinical application

microRNAs in cardiovascular disease – clinical application

MicroRNAs in Heart Failure

Biomarkers in Aortic Stenosis: A Systematic Review

Contact Info

Product

Resources

About